A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A phase 2/3 trial testing Evorpacept in gastric & gastro-oesophageal junction cancer, active and no longer recruiting.
Overview
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) is a phase 2/3 interventional study registered as NCT05002127, led by ALX Oncology with Eli Lilly and, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). Planned enrolment is 127 participants (actual). The study started in 2022-01-15 and primary completion is expected in 2024-05-24. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TreatmentCinrebafusp alfa
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.